Management of CLL and the Role of Minimal Residual Disease

Management of CLL and the Role of Minimal Residual Disease

MAY 12th, 2021 - 6-7PM Eastern

Virtual Zoom

Presented by Dr. Matthew Davids, MD, MMSc

Associate Director of the CLL Center

Dana-Farber Cancer Institute

Objectives:

• Examine the data supporting MRD as a prognostic marker

• Highlight the increasing relevance of MRD as a response assessment tool in the context of novel therapies

• Explore practical questions related to the use of MRD, such as how to define "undetectable" MRD

• Present the features of different resting methodologies

• Discuss the clinical situations and patient types in which MRD may be used to inform clinical management

Click to REGISTER